CD34 and leukemia: To this end, we examined in depth the anti-leukaemia activity of CAR.CD123-NK cells against all myeloid maturation subsets of the selected AML samples (Fig. 4A shows the percentage of CD38+CD34−, CD38+CD34+, CD38−CD34+ cell subsets in the 4 AML samples, and Fig. 4B reports the percentage of CD123+ cells for each mature myeloid subset).